Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00866775 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 193
- Enrollment target
NCT00866775 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 193 participants.
The verdict
NCT00866775, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 193 participants
- Enrollment target
Study Summary
This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
Interventions
- DRUG Eslicarbazepine acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00866775
The ClinicalTrials.gov registry entry for NCT00866775 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eslicarbazepine acetate is the first listed.
NCT00866775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00866775 about?
NCT00866775 is a clinical study titled "Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs". This is an 18-week, double-blind, multicenter study with gradual conversion from previous antiepileptic therapy to eslicarbazepine acetate monotherapy in subjects with partial epilepsy.
What is the current status of trial NCT00866775?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 193 participants. The study started on 2009-04. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00866775?
The interventions under investigation include: Eslicarbazepine acetate (DRUG).
Who is sponsoring clinical trial NCT00866775?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.